In two separate moves, Biohaven seeks to repurpose failed Bristol Myers/Roche Duchenne drug while buying out small biotech - Endpoints News

As Biohaven reported its fourth quarter and full-year 2021 earnings to investors, the biotech unveiled two new deals — a licensing deal with a Big Pharma and an acquisition of a smaller company. Biohaven is in-licensing a Phase III-ready compound for spinal m…

As Biohaven reported its fourth quarter and full-year 2021 earnings to investors, the biotech unveiled two new deals a licensing deal with a Big Pharma and an acquisition of a smaller company. Bioha… [+3404 chars]

full article...